Roflumilast for asthma: Weighing the evidence

被引：5
作者：
Bateman, E. D. [1 ]
O'Byrne, P. M. [2 ]
Buhl, R. [3 ]
Rabe, K. F. [4 ,5 ]
机构：
[1] Univ Cape Town, Lung Inst, Dept Med, Div Pulmonol, ZA-7925 Cape Town, South Africa
[2] McMaster Univ, Firestone Inst Resp Hlth, Dept Med, Hamilton, ON L8S 4L8, Canada
[3] Mainz Univ Hosp, Dept Pulm, Mainz, Germany
[4] LungClin, Grosshansdorf, Germany
[5] Univ Kiel, Dept Med, Kiel, Germany
来源：
PULMONARY PHARMACOLOGY & THERAPEUTICS | 2015年 / 35卷
关键词：
Asthma; Roflumilast; Safety; Placebo; FEV1; ICS; OBSTRUCTIVE PULMONARY-DISEASE; PDE4 INHIBITOR ROFLUMILAST; RANDOMIZED CLINICAL-TRIALS; PHOSPHODIESTERASE-4; INHIBITOR; SPUTUM; BRONCHODILATORS; INFLAMMATION; EFFICACY; UPDATE;
D O I：
10.1016/j.pupt.2015.08.001
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：S1 / S3
页数：3
相关论文
共 24 条
  • [1] Corticosteroid resistance in patients with asthma and chronic obstructive pulmonary disease
    Barnes, Peter J.
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2013, 131 (03) : 636 - 645
  • [2] Efficacy and safety of roflumilast in the treatment of asthma
    Bateman, Eric D.
    Izquierdo, Jose Luis
    Harnest, Ulf
    Hofbauer, Peter
    Magyar, Pal
    Schinid-Wirlitsch, Christine
    Leichtl, Stefan
    Bredenbroeker, Dirk
    [J]. ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2006, 96 (05) : 679 - 686
  • [3] Pathological features and inhaled corticosteroid response of eosinophilic and non-eosinophilic asthma
    Berry, Mike
    Morgan, Angela
    Shaw, Dominick E.
    Parker, Deborah
    Green, Ruth
    Brightling, Christopher
    Bradding, Peter
    Wardlaw, Andrew J.
    Pavord, Ian D.
    [J]. THORAX, 2007, 62 (12) : 1043 - 1049
  • [4] Comparison of roflumilast, an oral anti-inflammatory, with beclomethasone dipropionate in the treatment of persistent asthma
    Bousquet, J
    Aubier, M
    Sastre, J
    Izquierdo, JL
    Adler, LM
    Hofbauer, P
    Rost, KD
    Harnest, U
    Kroemer, B
    Albrecht, A
    Bredenbröker, D
    [J]. ALLERGY, 2006, 61 (01) : 72 - 78
  • [5] Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease
    Brightling, CE
    McKenna, S
    Hargadon, B
    Birring, S
    Green, R
    Siva, R
    Berry, M
    Parker, D
    Monteiro, W
    Pavord, ID
    Bradding, P
    [J]. THORAX, 2005, 60 (03) : 193 - 198
  • [6] Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials
    Calverley, Peter M. A.
    Rabe, Klaus F.
    Goehring, Udo-Michael
    Kristiansen, Soren
    Fabbri, Leonardo M.
    Martinez, Fernando J.
    [J]. LANCET, 2009, 374 (9691) : 685 - 694
  • [7] An update on bronchodilators in Phase I and II clinical trials
    Cazzola, Mario
    Rogliani, Paola
    Segreti, Andrea
    Matera, Maria Gabriella
    [J]. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2012, 21 (10) : 1489 - 1501
  • [8] Effect of high dose inhaled steroid on cells, cytokines, and proteases in induced sputum in chronic obstructive pulmonary disease
    Culpitt, SV
    Maziak, W
    Loukidis, S
    Nightingale, JA
    Matthews, JL
    Barnes, PJ
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1999, 160 (05) : 1635 - 1639
  • [9] Cyclic nucleotide phosphodiesterase (PDE) inhibitors and immunomodulation
    Essayan, DM
    [J]. BIOCHEMICAL PHARMACOLOGY, 1999, 57 (09) : 965 - 973
  • [10] Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials
    Fabbri, Leonardo M.
    Calverley, Peter M. A.
    Luis Izquierdo-Alonso, Jose
    Bundschuh, Daniela S.
    Brose, Manja
    Martinez, Fernando J.
    Rabe, Klaus F.
    [J]. LANCET, 2009, 374 (9691) : 695 - 703
123